144 related articles for article (PubMed ID: 7910994)
21. [Efficacy of gastrosidine (famotidine) in the treatment of gastroesophageal reflux at the reflux esophagitis stage].
Vasil'ev IuV; Li IA
Eksp Klin Gastroenterol; 2002; (4):30-3, 131. PubMed ID: 12503271
[TBL] [Abstract][Full Text] [Related]
22. Treatment of reflux esophagitis resistant to H2-receptor antagonists with lansoprazole, a new H+/K(+)-ATPase inhibitor: a controlled, double-blind study. Lansoprazole Study Group.
Feldman M; Harford WV; Fisher RS; Sampliner RE; Murray SB; Greski-Rose PA; Jennings DE
Am J Gastroenterol; 1993 Aug; 88(8):1212-7. PubMed ID: 8101695
[TBL] [Abstract][Full Text] [Related]
23. [Effect of oxmetidine and ranitidine on reflux behavior in patients with esophagitis].
Weiser HF; Gubernatis G; Siewert JR
Z Gastroenterol; 1983 Oct; 21(10):580-4. PubMed ID: 6139923
[TBL] [Abstract][Full Text] [Related]
24. How do you spell relief in reflux esophagitis? PPI!
Fennerty MB
Gastroenterology; 1996 Sep; 111(3):826-7. PubMed ID: 8780593
[No Abstract] [Full Text] [Related]
25. Hiatus hernia and reflux esophagitis.
Spiro HM
Hosp Pract (Off Ed); 1994 Jan; 29(1):51-4, 61, 65-6. PubMed ID: 7904609
[No Abstract] [Full Text] [Related]
26. [Drug treatment of reflux esophagitis: effects of strong gastric acid inhibition].
Jansen JB; Lamers CB
Ned Tijdschr Geneeskd; 1989 Apr; 133(13):662-5. PubMed ID: 2566126
[No Abstract] [Full Text] [Related]
27. Towards an increased efficacy of acid inhibition in the treatment of erosive oesophagitis.
Lambert R
J Gastroenterol Hepatol; 1996 Oct; 11(10):897-9. PubMed ID: 8912122
[No Abstract] [Full Text] [Related]
28. [Therapeutic approaches in gastroesophageal reflux disease].
Rühl A; Erckenbrecht JF
Z Gastroenterol; 1990 Apr; 28 Suppl 1():60-6; discussion 75-7. PubMed ID: 1972603
[No Abstract] [Full Text] [Related]
29. Effect of cisapride on relapse of reflux oesophagitis, healed with an antisecretory drug.
Tytgat GN; Anker Hansen OJ; Carling L; de Groot GH; Geldof H; Glise H; Efskind P; Elsborg L; Karvonen AL; Ohlin B
Scand J Gastroenterol; 1992; 27(3):175-83. PubMed ID: 1502478
[TBL] [Abstract][Full Text] [Related]
30. [Therapy of reflux disease].
Koelz HR; Siewert JR; Blum AL
Dtsch Med Wochenschr; 1986 Jan; 111(3):105-9. PubMed ID: 2866943
[No Abstract] [Full Text] [Related]
31. [Concerning the discussion article by I. A. Morozov "Choice of the gastroenterologist"].
Gorshkov VA
Klin Med (Mosk); 2002; 80(9):66-70. PubMed ID: 12416232
[No Abstract] [Full Text] [Related]
32. [Gastroesophageal reflux (round table I)].
Caussignac Y; Martin S; Jobin G; Beauchamp G
Union Med Can; 1995 Mar; 124(1):26-31. PubMed ID: 8540149
[No Abstract] [Full Text] [Related]
33. Gastroesophageal reflux: diagnosis and management.
Richter JE
Hosp Pract (Off Ed); 1992 Jan; 27(1):59-66. PubMed ID: 1346142
[TBL] [Abstract][Full Text] [Related]
34. Lansoprazole versus omeprazole in the treatment of reflux esophagitis.
Vcev A; Stimac D; Vceva A; Rubinić M; Ivandić A; Ivanis N; Horvat D; Volarić M; Karner I
Acta Med Croatica; 1997; 51(3):171-4. PubMed ID: 9248117
[TBL] [Abstract][Full Text] [Related]
35. Factors influencing corpus argyrophil cell density and hyperplasia in reflux esophagitis patients treated with antisecretory drugs and controls.
Diebold MD; Richardson S; Duchateau A; Bigard MA; Colin R; Cortot A; Fauchère JL; Zeitoun P
Dig Dis Sci; 1998 Aug; 43(8):1629-35. PubMed ID: 9724142
[TBL] [Abstract][Full Text] [Related]
36. [Is antisecretory therapy of patients with chemical burn of the esophagus mandatory?].
Abakumov MM; Pinchuk TP; ll'iashenko LG
Khirurgiia (Mosk); 2007; (1):20-4. PubMed ID: 17426684
[TBL] [Abstract][Full Text] [Related]
37. [Intragastric pH modifications induced by antisecretory treatments].
Vallot T; Galmiche JP; Gouilloud-Celle S; Mignon M
Gastroenterol Clin Biol; 1991; 15(5 ( Pt 2)):80C-87C. PubMed ID: 1680770
[No Abstract] [Full Text] [Related]
38. The effect of H2-receptor antagonist and proton pump inhibitor on microbial proliferation in the stomach.
Wang K; Lin HJ; Perng CL; Tseng GY; Yu KW; Chang FY; Lee SD
Hepatogastroenterology; 2004; 51(59):1540-3. PubMed ID: 15362796
[TBL] [Abstract][Full Text] [Related]
39. [What is the role of H2 receptor blockers today in ulcer therapy?].
Creutzfeldt W
Internist (Berl); 1996 Sep; 37(9):937-8. PubMed ID: 8964690
[No Abstract] [Full Text] [Related]
40. Healing, relapse rates and prophylaxis of reflux esophagitis.
Glise H
Scand J Gastroenterol Suppl; 1989; 156():57-64. PubMed ID: 2568016
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
